HORMONE RECEPTOR/GROWTH FACTOR RECEPTOR-NEGATIVE BREAST CANCER

Clinical trials for HORMONE RECEPTOR/GROWTH FACTOR RECEPTOR-NEGATIVE BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HORMONE RECEPTOR/GROWTH FACTOR RECEPTOR-NEGATIVE BREAST CANCER trials appear

Sign up with your email to follow new studies for HORMONE RECEPTOR/GROWTH FACTOR RECEPTOR-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for Tough-to-Treat breast cancer: experimental combo enters human trials

Disease control Ongoing

This study is testing whether adding a new, experimental drug called onvansertib to a standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread. The first part finds the safest dose, and the second part checks if the co…

Matched conditions: HORMONE RECEPTOR/GROWTH FACTOR RECEPTOR-NEGATIVE BREAST CANCER

Phase: PHASE1, PHASE2 • Sponsor: Antonio Giordano, MD • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

HORMONE RECEPTOR/GROWTH FACTOR RECEPTOR-NEGATIVE BREAST CANCER

Get alerted when new HORMONE RECEPTOR/GROWTH FACTOR RECEPTOR-NEGATIVE BREAST CANCER trials appear

New hope for Tough-to-Treat breast cancer: experimental combo enters human trials